- Home
- SAVA vs CUE Comparison
SAVA vs CUE Comparison
Compare SAVA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- CUE
- Stock Information
- Founded
- SAVA 1998
- CUE 2014
- Country
- SAVA United States
- CUE United States
- Employees
- SAVA N/A
- CUE N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- CUE Health Care
- Exchange
- SAVA Nasdaq
- CUE Nasdaq
- Market Cap
- SAVA 113.8M
- CUE 94.4M
- IPO Year
- SAVA N/A
- CUE 2018
- Fundamental
- Price
- SAVA $2.55
- CUE $1.32
- Analyst Decision
- SAVA Buy
- CUE Strong Buy
- Analyst Count
- SAVA 3
- CUE 5
- Target Price
- SAVA $111.50
- CUE $5.00
- AVG Volume (30 Days)
- SAVA 1.3M
- CUE 195.8K
- Earning Date
- SAVA 03-07-2025
- CUE 03-10-2025
- Dividend Yield
- SAVA N/A
- CUE N/A
- EPS Growth
- SAVA N/A
- CUE N/A
- EPS
- SAVA N/A
- CUE N/A
- Revenue
- SAVA N/A
- CUE $9,532,000.00
- Revenue This Year
- SAVA N/A
- CUE $73.11
- Revenue Next Year
- SAVA N/A
- CUE $11.02
- P/E Ratio
- SAVA N/A
- CUE N/A
- Revenue Growth
- SAVA N/A
- CUE 149.53
- 52 Week Low
- SAVA $2.23
- CUE $0.45
- 52 Week High
- SAVA $42.20
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- SAVA 41.47
- CUE 48.32
- Support Level
- SAVA $2.25
- CUE $1.22
- Resistance Level
- SAVA $2.36
- CUE $1.54
- Average True Range (ATR)
- SAVA 0.14
- CUE 0.11
- MACD
- SAVA 0.17
- CUE -0.01
- Stochastic Oscillator
- SAVA 50.85
- CUE 35.29
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.